AKTS

Rating neutralAI Memo

Aktis Oncology

As of 2026-07-29/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-29 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

AKY-2519 basket-trial expansion • 2026-12-31

Base target: $27 / p=50% prob

Biggest risk

The programs remain early-stage with unproven efficacy and safety. The cited Q1 EPS miss, insider selling, low coverage, and negative deterministic return prior support a cautious rather than bullish interpretation.

Invalidation

Break below $15 or thesis failure.

What would change my mind?

Aktis has advanced two radiopharmaceutical programs into Phase 1b, has Fast Track designation for AKY-1189, and expects multiple clinical data opportunities beginning in 2027. [#SEC-8K-2026-05-11]

Research note

Recommendation

neutral

Confidence

medium

As of

2026-07-29

Base target

$27

p=50%

Bull target

$40

p=20%

Bear target

$15

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-earnings miss and insider-sale overhang
Preliminary clinical data from AKY-2519 and AKY-1189
Aktis has advanced two radiopharmaceutical programs into Phase 1b, has Fast Track designation for AKY-1189, and expects multiple clinical data opportunities beginning in 2027.

BearKey bullets

Clinical efficacy, safety, and durability remain unproven for AKY-1189 and AKY-2519.
Delays in enrollment, the planned second AKY-2519 Phase 1b trial, or 2027 data readouts could weaken the thesis.
[#SEC-8K-2026-05-11]

WatchKey bullets

AKY-2519 basket-trial expansion

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $27 (p=50%)

Target spread vs base: +48% / -44%

Scenario probabilities

Bull Target: $40 (p=20%)Base Target: $27 (p=50%)Bear Target: $15 (p=30%)

Commentary

News tone is mixed-to-cautious: clinical progress and planned 2027 data provide forward hooks, while AP/Zacks coverage highlighted an EPS miss and recent insider filings showed open-market sales. Social sentiment, options skew, short interest, employee ratings, and post-print analyst revisions are unavailable; low coverage limits confidence.

As of 2026-07-29 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Aktis has advanced two radiopharmaceutical programs into Phase 1b, has Fast Track designation for AKY-1189, and expects multiple clinical data opportunities beginning in 2027. [#SEC-8K-2026-05-11]

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-earnings miss and insider-sale overhang
Preliminary clinical data from AKY-2519 and AKY-1189

Scenarios

Bull Target (Scenario probability)

$40 / p=20% prob

Base Target (Scenario probability)

$27 / p=50% prob

Bear Target (Scenario probability)

$15 / p=30% prob

Analysis 2026-07-29 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.25

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
AKY-2519 basket-trial expansion
Aktis initiated the AKY-2519 Phase 1b mCRPC trial and plans a second Phase 1b basket trial in additional solid tumors during the second half of 2026. Execution would provide an intermediate development milestone. [#SEC-8K-2026-05-11]
Prob 55.00% • Move 10.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

Post-earnings miss and insider-sale overhang
2026-08-31
Q1 results were reported as an EPS miss versus the cited Zacks consensus despite revenue above expectations; COO and CMO Form 4 filings also show open-market sales on July 8. These factors may keep near-term sentiment cautious. [#PR-EARNINGS-2026-05-12] [#SEC-FORM4-2026-07-10]
Prob 70% • Move -6% • Priced-in 65%

Long-term Catalysts

Months to a year

Preliminary clinical data from AKY-2519 and AKY-1189
2027-03-31
Management expects preliminary AKY-2519 data in 2027 and preliminary AKY-1189 Phase 1b data in the first quarter of 2027. These are the main potential value inflection points, but efficacy and safety remain unproven. [#SEC-8K-2026-05-11]
Prob 50% • Move 22% • Priced-in 30%

Risks

Clinical efficacy, safety, and durability remain unproven for AKY-1189 and AKY-2519.
Delays in enrollment, the planned second AKY-2519 Phase 1b trial, or 2027 data readouts could weaken the thesis. [#SEC-8K-2026-05-11]
July 8 open-market sales by the COO and CMO may contribute to investor concern, although insider transactions do not establish operating performance. [#SEC-FORM4-2026-07-10]
Low coverage and loose peers reduce confidence in target-based valuation comparisons.
The reported Q1 EPS miss versus cited consensus may pressure sentiment. [#PR-EARNINGS-2026-05-12]

Peers

Symbol	Summary
ARDX	Loose same-sector and market-cap context; the packet does not establish modality or indication overlap, so it is not a direct read-through.
ORIC	Small-cap biopharma context with limited demonstrated comparability to Aktis's targeted radiopharmaceutical programs.
ETON	Approximate market-cap and sector comparison only; business and development-stage differences limit valuation usefulness.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-07-29

Loading AI feed…

Symbol

Summary

ARDX

Loose same-sector and market-cap context; the packet does not establish modality or indication overlap, so it is not a direct read-through.

ORIC

Small-cap biopharma context with limited demonstrated comparability to Aktis's targeted radiopharmaceutical programs.

ETON

Approximate market-cap and sector comparison only; business and development-stage differences limit valuation usefulness.